28 November 2022 - The CGRP (calcitonin gene-related peptide) inhibitors, developed to prevent adult migraines, have recently been registered on the list of insurance beneficiaries, but their reimbursement standards are unrealistic, experts said.

“The reimbursement criteria for CGRP inhibitors have been set by Western standards and are too unrealistic to be applied to Korean patients,” said Kim Byeong-su, a director at the Korea Headache Society (KHS) and a neurologist at Bundang Jesaeng General Hospital, Sunday. “The Government should try to relax the criteria to suit Korean conditions better.”

Read Korea Biomedical Review article